Terbinafine for CSA-AKI Prevention

Primary Objective: To evaluate the efficacy and safety of perioperative oral terbinafine in reducing the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI).Secondary Objectives:To assess the effects of terbinafine on the severity of post-cardiac surgery AKI, length of hospital stay, and 30-day major adverse kidney events (MAKE30);To evaluate its impacts on biomarkers of renal injury and inflammation.

NCT Number	NCT07738328
Lead Sponsor	Guangdong Provincial People's Hospital
Conditions	Acute Kidney Injury, Cardiac Surgical Procedures
Enrollment	208 participants
Start Date	2026-09-01
Primary Completion	2028-04-01 (estimated)
Study Completion	2028-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-31